View of Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis

Return to Article Details Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis Download Download PDF